CN120647702A - 药剂、组合物及其相关方法 - Google Patents
药剂、组合物及其相关方法Info
- Publication number
- CN120647702A CN120647702A CN202510741418.6A CN202510741418A CN120647702A CN 120647702 A CN120647702 A CN 120647702A CN 202510741418 A CN202510741418 A CN 202510741418A CN 120647702 A CN120647702 A CN 120647702A
- Authority
- CN
- China
- Prior art keywords
- compound
- insulin
- pharmaceutically acceptable
- glucose
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| US62/508,730 | 2017-05-19 | ||
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
| CN201880027339.7A CN110545822A (zh) | 2017-05-19 | 2018-05-01 | 药剂、组合物及其相关方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880027339.7A Division CN110545822A (zh) | 2017-05-19 | 2018-05-01 | 药剂、组合物及其相关方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120647702A true CN120647702A (zh) | 2025-09-16 |
Family
ID=64274560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510741418.6A Pending CN120647702A (zh) | 2017-05-19 | 2018-05-01 | 药剂、组合物及其相关方法 |
| CN201880027339.7A Pending CN110545822A (zh) | 2017-05-19 | 2018-05-01 | 药剂、组合物及其相关方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880027339.7A Pending CN110545822A (zh) | 2017-05-19 | 2018-05-01 | 药剂、组合物及其相关方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3624809A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7224303B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN120647702A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018269403B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3061893A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2765286C2 (cg-RX-API-DMAC7.html) |
| SA (1) | SA519410561B1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909932YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018212980A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002305073A1 (en) * | 2001-03-22 | 2002-10-08 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| US7488720B2 (en) * | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| EP2192905A4 (en) | 2007-08-29 | 2010-11-10 | Adam Lubin | METHOD FOR SELECTIVE THERAPY OF DISEASE |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| CN105377271A (zh) | 2013-03-15 | 2016-03-02 | 全技术公司 | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 |
| MX2016011897A (es) * | 2014-03-14 | 2017-04-27 | Alltech Inc | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
-
2018
- 2018-05-01 CN CN202510741418.6A patent/CN120647702A/zh active Pending
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/ja active Active
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 AU AU2018269403A patent/AU2018269403B2/en active Active
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/zh active Pending
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en not_active Ceased
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/ru active
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/ar unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2765286C2 (ru) | 2022-01-28 |
| NZ758538A (en) | 2025-08-29 |
| JP7224303B2 (ja) | 2023-02-17 |
| WO2018212980A1 (en) | 2018-11-22 |
| CN110545822A (zh) | 2019-12-06 |
| EP3624809A1 (en) | 2020-03-25 |
| US11613552B2 (en) | 2023-03-28 |
| BR112019022918A2 (pt) | 2020-05-26 |
| RU2019134865A (ru) | 2021-06-21 |
| RU2019134865A3 (cg-RX-API-DMAC7.html) | 2021-06-30 |
| AU2018269403B2 (en) | 2025-03-27 |
| EP3624809A4 (en) | 2021-03-03 |
| US11014954B2 (en) | 2021-05-25 |
| JP2020520904A (ja) | 2020-07-16 |
| SA519410561B1 (ar) | 2024-03-06 |
| US20210238216A1 (en) | 2021-08-05 |
| US20200123191A1 (en) | 2020-04-23 |
| CA3061893A1 (en) | 2018-11-22 |
| AU2018269403A1 (en) | 2019-11-14 |
| SG11201909932YA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102764247B1 (ko) | 셀레노유기 화합물의 조성물 및 그의 사용 방법 | |
| TWI423819B (zh) | 用於調節trpa1功能之化合物 | |
| RU2663127C2 (ru) | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией | |
| JP7637050B2 (ja) | 少なくとも1つのグリシン又はその誘導体と、少なくとも1つのn-アセチルシステイン又はその誘導体と、少なくとも1つのニコチンアミドリボシド又はnad+前駆体と、を使用する組成物及び方法 | |
| US6521645B2 (en) | Methods for the treatment and prevention of urinary stone disease | |
| KR20100080561A (ko) | 5-리폭시게나아제 활성화 단백질(flap) 억제제 | |
| US11613552B2 (en) | Pharmaceutical agents, compositions, and methods relating thereto | |
| Kim et al. | Enhancing effect of indirubin derivatives on 1, 25-dihydroxyvitamin D3-and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells | |
| HK40017181A (en) | Pharmaceutical agents, compositions, and methods relating thereto | |
| CN114521142B (zh) | 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法 | |
| TW202345779A (zh) | eNAMPT增加劑、沉默調節蛋白活化或表現增強劑、NAD+增加劑、及老化細胞抑制劑 | |
| WO2015009883A1 (en) | Activators of nad-dependent protein deacteylases and uses thereof | |
| CN110799518B (zh) | 钴胺素衍生物及其用于治疗因缺乏维生素b12供应引起的疾病的用途 | |
| US8093233B2 (en) | Agent for inhibiting visceral fat accumulation | |
| BR112019022918B1 (pt) | Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos | |
| EP3144001B1 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| JP2015160847A (ja) | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 | |
| US9193681B1 (en) | Propionic acids, propionic acid esters, and related compounds | |
| US20230346765A1 (en) | Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof | |
| US20150297564A1 (en) | Method of enhancing glucose-stimulated insulin secretion and of treating type 2 diabetes or hypoglycemia | |
| WO2023193809A1 (zh) | Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途 | |
| TW202430503A (zh) | 新穎治療分子 | |
| TW202233173A (zh) | 包括15-HETrE之醫藥組合物及其使用方法 | |
| HK40068410A (en) | Chronic kidney disease treatment or prevention method | |
| MXPA96002577A (en) | Treatment of arterioesclerosis and xant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40132627 Country of ref document: HK |